Eliza Blanchette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eliza Blanchette has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kyle O. Rove
Department of Pediatric Urology, Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA
3 shared publications - Margret Bock
Department of Pediatric Nephrology Children's Hospital Colorado Aurora Colorado USA
3 shared publications - Darren Ha
Pediatric Urology Research Enterprise, Department of Pediatric Urology, Children's Hospital Colorado, Aurora, CO, USA; University of Colorado School of Medicine, Aurora, CO, USA
2 shared publications - Eric Benz
Department of Pediatric Nephrology Children's Hospital Colorado Aurora Colorado USA
2 shared publications Vijaya M. Vemulakonda
Department of Surgery, Division of Urology, University of Colorado School of Medicine, Aurora, CO, USA; Pediatric Urology Research Enterprise, Department of Pediatric Urology, Children's Hospital Colorado, Aurora, CO, USA
2 shared publications- Aaron Wightman
Department of Pediatrics University of Washington Seattle Washington USA
1 shared publication
Latest Publications
- 1 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70514
Excellent Long‐Term Outcome in a Staged, Simultaneous Liver‐Kidney Transplantation of a Highly Sensitized Pediatric Patient With B and T Cell Positive Crossmatch
Background: While immunologically challenging and controversial, we report a successful case of same donor staged simultaneous liver‐kidney transplant (SLK) in a highly sensitized small child against a positive cytotoxic crossmatch (XM) and high Class I/II donor‐specific antibody (DSA) titers. Methods: Our immunologic approach included: Rituximab given prior to liver transplant (LT) and Methylprednisone and Basiliximab during the anhepatic phase. A flow XM obtained 30 min after LT was negative for T cell flow, while B cell flow remained positive, presumably related to Rituximab. The donor kidney was pumped overnight. Tacrolimus (Tac) and Cellcept (MMF) were initiated. Results: On return to the operating room 18 h later, the T cell flow XM was negative, and the B cell flow XM was weakly positive. Eculuzimab and MP were given at renal graft perfusion. Immediate urine output occurred. Normalization of liver and kidney markers was noted. At 5 years post staged SLK, there is excellent liver and kidney function and no evidence of de‐novo DSA. Interestingly, non‐HLA antibody mediated rejection of the liver only was observed 1 year post transplant. Conclusions: We present the successful staged SLK of a complex, highly sensitized child in the setting of high titers of Class I/II DSAs against positive XMs. Sophisticated immunologic management and delay of kidney transplantation by 18 h, presumably allowing the liver allograft to absorb circulating DSAs and T‐cells, resulted in excellent short and long‐term graft function.
- 1 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70514
Excellent Long‐Term Outcome in a Staged, Simultaneous Liver‐Kidney Transplantation of a Highly Sensitized Pediatric Patient With B and T Cell Positive Crossmatch
Background: While immunologically challenging and controversial, we report a successful case of same donor staged simultaneous liver‐kidney transplant (SLK) in a highly sensitized small child against a positive cytotoxic crossmatch (XM) and high Class I/II donor‐specific antibody (DSA) titers. Methods: Our immunologic approach included: Rituximab given prior to liver transplant (LT) and Methylprednisone and Basiliximab during the anhepatic phase. A flow XM obtained 30 min after LT was negative for T cell flow, while B cell flow remained positive, presumably related to Rituximab. The donor kidney was pumped overnight. Tacrolimus (Tac) and Cellcept (MMF) were initiated. Results: On return to the operating room 18 h later, the T cell flow XM was negative, and the B cell flow XM was weakly positive. Eculuzimab and MP were given at renal graft perfusion. Immediate urine output occurred. Normalization of liver and kidney markers was noted. At 5 years post staged SLK, there is excellent liver and kidney function and no evidence of de‐novo DSA. Interestingly, non‐HLA antibody mediated rejection of the liver only was observed 1 year post transplant. Conclusions: We present the successful staged SLK of a complex, highly sensitized child in the setting of high titers of Class I/II DSAs against positive XMs. Sophisticated immunologic management and delay of kidney transplantation by 18 h, presumably allowing the liver allograft to absorb circulating DSAs and T‐cells, resulted in excellent short and long‐term graft function.
- 12 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70427
Substance Use Patterns in Pediatric Solid Organ Transplant Candidates: Impact After Transplant
Background: The prevalence and impact of substance use in pediatric solid organ transplant candidates and how these relate to post‐transplant outcomes are not well studied. Methods: The Alcohol and Substance Use modules of the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS) were administered to all patients aged 12–18 who underwent heart, liver, or kidney transplant evaluation at our institution between 6/2020 and 12/2023. A total of 55 patients underwent KSADS testing at evaluation, received a transplant, and had adequate follow‐up for inclusion. Following transplant, outcome measures included time‐weighted coefficient of variance (TW‐CoV) in serum tacrolimus level and organ rejection during follow‐up. Results: A total of 9 patients (16%) endorsed ever trying any substance at time of pre‐transplant evaluation. Past and present substance use impairment symptoms based on DSM‐5 substance use impairment criteria pre‐transplant were significantly associated with TW‐CoV (past: r = 0.37, p = 0.006; present: r = 0.39, p = 0.003) in tacrolimus levels post‐transplant. Past substance use impairment symptoms pre‐transplant were associated with organ rejection by 1 year post‐transplant ( r = 0.32, p = 0.034). For patients who endorsed ever trying any substance, or trying any substance 5+ times, there were no significant differences for either group in adherence or rejection episodes when compared to patients who reported never trying any substance. Conclusion: Rates of substance use are relatively low in this population of pediatric solid organ transplant candidates. Substance use impairment symptoms identified pre‐transplant are associated with increased rejection episodes and surrogate markers for non‐adherence post‐transplant.
- 12 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70427
Substance Use Patterns in Pediatric Solid Organ Transplant Candidates: Impact After Transplant
Background: The prevalence and impact of substance use in pediatric solid organ transplant candidates and how these relate to post‐transplant outcomes are not well studied. Methods: The Alcohol and Substance Use modules of the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS) were administered to all patients aged 12–18 who underwent heart, liver, or kidney transplant evaluation at our institution between 6/2020 and 12/2023. A total of 55 patients underwent KSADS testing at evaluation, received a transplant, and had adequate follow‐up for inclusion. Following transplant, outcome measures included time‐weighted coefficient of variance (TW‐CoV) in serum tacrolimus level and organ rejection during follow‐up. Results: A total of 9 patients (16%) endorsed ever trying any substance at time of pre‐transplant evaluation. Past and present substance use impairment symptoms based on DSM‐5 substance use impairment criteria pre‐transplant were significantly associated with TW‐CoV (past: r = 0.37, p = 0.006; present: r = 0.39, p = 0.003) in tacrolimus levels post‐transplant. Past substance use impairment symptoms pre‐transplant were associated with organ rejection by 1 year post‐transplant ( r = 0.32, p = 0.034). For patients who endorsed ever trying any substance, or trying any substance 5+ times, there were no significant differences for either group in adherence or rejection episodes when compared to patients who reported never trying any substance. Conclusion: Rates of substance use are relatively low in this population of pediatric solid organ transplant candidates. Substance use impairment symptoms identified pre‐transplant are associated with increased rejection episodes and surrogate markers for non‐adherence post‐transplant.
- 9 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70241
Outcomes of Steroid Based Versus Steroid Minimizing Immunosuppression in Pediatric Kidney Transplant Recipients: A NAPRTCS Study
Background: Early studies evaluating steroid‐minimization (SM) employed immunosuppression that is not representative of the modern era of immunosuppression. We hypothesized that current SM‐based immunosuppression protocols offer unique advantages for pediatric kidney transplant recipients (pKTR) without compromising allograft and patient outcomes. Methods: This is a retrospective study of 3263 pKTR between 2000 and 2019 from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Study participants were grouped as SM and steroid based (SB) based on corticosteroids use at 30 days post‐transplant. Primary outcomes of interest were allograft function and survival. Secondary outcomes included linear growth, obesity and hypertension. Results: A SB regimen was used in 2312 (70.9%) and SM in 951 (29.1%). Comparison of the allograft function showed that SM was associated with a significantly higher estimated glomerular filtration rate (eGFR) at 1, 2, and 3 years post‐transplant compared to SB. Kaplan–Meier curves showed that SM was associated with significantly less allograft loss ( p = 0.01) compared to SB while there was no significant difference in allograft survival when stratified by induction and steroid regimen ( p = 0.49). Multivariate Cox regression showed that the SB regimen was not associated with improved graft survival (hazard ratio 1.38 [0.89–2.16]; p = 0.15). Secondary outcome analysis showed significantly better linear growth and less obesity and hypertension in SM compared to SB. Conclusions: SM immunosuppression was not associated with decreased allograft rejection, function or survival, and was associated with a reduced risk of secondary complications. In patients receiving contemporary, tacrolimus‐based maintenance immunosuppression, a SM regimen may be preferred.
- 9 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70241
Outcomes of Steroid Based Versus Steroid Minimizing Immunosuppression in Pediatric Kidney Transplant Recipients: A NAPRTCS Study
Background: Early studies evaluating steroid‐minimization (SM) employed immunosuppression that is not representative of the modern era of immunosuppression. We hypothesized that current SM‐based immunosuppression protocols offer unique advantages for pediatric kidney transplant recipients (pKTR) without compromising allograft and patient outcomes. Methods: This is a retrospective study of 3263 pKTR between 2000 and 2019 from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Study participants were grouped as SM and steroid based (SB) based on corticosteroids use at 30 days post‐transplant. Primary outcomes of interest were allograft function and survival. Secondary outcomes included linear growth, obesity and hypertension. Results: A SB regimen was used in 2312 (70.9%) and SM in 951 (29.1%). Comparison of the allograft function showed that SM was associated with a significantly higher estimated glomerular filtration rate (eGFR) at 1, 2, and 3 years post‐transplant compared to SB. Kaplan–Meier curves showed that SM was associated with significantly less allograft loss ( p = 0.01) compared to SB while there was no significant difference in allograft survival when stratified by induction and steroid regimen ( p = 0.49). Multivariate Cox regression showed that the SB regimen was not associated with improved graft survival (hazard ratio 1.38 [0.89–2.16]; p = 0.15). Secondary outcome analysis showed significantly better linear growth and less obesity and hypertension in SM compared to SB. Conclusions: SM immunosuppression was not associated with decreased allograft rejection, function or survival, and was associated with a reduced risk of secondary complications. In patients receiving contemporary, tacrolimus‐based maintenance immunosuppression, a SM regimen may be preferred.
- 17 October 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (1) , 225-230
Pediatric Patients Undergoing Enterocystoplasty and Risk of Metabolic Disease: A Single Center Retrospective Study
Introduction: Enterocystoplasty is a procedure that uses the ileum to augment a small bladder reservoir. Because many of the anorexigenic intestinal hormones are produced in the ileum, this study evaluates the incidence of developing metabolic complications in patients undergoing augmentation. Methods: We retrospectively reviewed all patients who underwent an enterocystoplasty at a large pediatric tertiary center covering seven states. Because a large portion of patients undergoing enterocystoplasty had spina bifida, we included a separate control registry of spina bifida patients without augments. We evaluated both demographic and clinical risk factors for developing overweight, obesity, hypertension, type 2 diabetes, and metabolic dysfunction‐associated steatotic liver disease. Results: A total of 112 patients were eligible for analysis, with a median follow up time of 5 years. Approximately 61% of this cohort developed overweight or obesity. We did not find enterocystoplasty to be a risk factor in developing overweight or obesity (HR: 1.3, 95% CI: 0.865–1.982). Notable risk factors were having spina bifida and having an enterocystoplasty before puberty ( p = 0.001 and p < 0.001, respectively). The odds of developing overweight in the spina bifida patients was 4.2 (95% CI: 1.8–9.8). After adjusting for mobility, the hazard ratio of developing overweight or obesity was 3.48 (95% CI: 1.72–7.03) if a patient had enterocystoplasty before puberty versus later. Conclusion: The rates of developing overweight or overweight are high in this cohort. Specific risk factors for developing overweight include having spina bifida and undergoing enterocystoplasty before puberty. Clinical Trial Registration Number: None, as this is a retrospective study not involved in the study of a new medication or procedure.
- 17 October 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (1) , 225-230
Pediatric Patients Undergoing Enterocystoplasty and Risk of Metabolic Disease: A Single Center Retrospective Study
Introduction: Enterocystoplasty is a procedure that uses the ileum to augment a small bladder reservoir. Because many of the anorexigenic intestinal hormones are produced in the ileum, this study evaluates the incidence of developing metabolic complications in patients undergoing augmentation. Methods: We retrospectively reviewed all patients who underwent an enterocystoplasty at a large pediatric tertiary center covering seven states. Because a large portion of patients undergoing enterocystoplasty had spina bifida, we included a separate control registry of spina bifida patients without augments. We evaluated both demographic and clinical risk factors for developing overweight, obesity, hypertension, type 2 diabetes, and metabolic dysfunction‐associated steatotic liver disease. Results: A total of 112 patients were eligible for analysis, with a median follow up time of 5 years. Approximately 61% of this cohort developed overweight or obesity. We did not find enterocystoplasty to be a risk factor in developing overweight or obesity (HR: 1.3, 95% CI: 0.865–1.982). Notable risk factors were having spina bifida and having an enterocystoplasty before puberty ( p = 0.001 and p < 0.001, respectively). The odds of developing overweight in the spina bifida patients was 4.2 (95% CI: 1.8–9.8). After adjusting for mobility, the hazard ratio of developing overweight or obesity was 3.48 (95% CI: 1.72–7.03) if a patient had enterocystoplasty before puberty versus later. Conclusion: The rates of developing overweight or overweight are high in this cohort. Specific risk factors for developing overweight include having spina bifida and undergoing enterocystoplasty before puberty. Clinical Trial Registration Number: None, as this is a retrospective study not involved in the study of a new medication or procedure.
- Open Access
- 6 December 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (2) , 460-469
Opioid prescribing patterns and the effect of chronic kidney disease in pediatric urology population: A retrospective cohort analysis
- 6 December 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (2) , 460-469
Open AccessOpioid prescribing patterns and the effect of chronic kidney disease in pediatric urology population: A retrospective cohort analysis
- Open Access
- 16 July 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (5) , 911-920
Risk of acute kidney injury after lower urinary tract reconstruction with early NSAID therapy: A propensity matched retrospective analysis
- 16 July 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (5) , 911-920
Open AccessRisk of acute kidney injury after lower urinary tract reconstruction with early NSAID therapy: A propensity matched retrospective analysis
- 14 June 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (12) , 3945-3951
Caregiver burden in pediatric dialysis: application of the Paediatric Renal Caregiver Burden Scale
Background Caring for a child with kidney failure on dialysis profoundly impacts caregivers’ lives, yet the depth of this burden is not well understood. The Paediatric Renal Caregiver Burden Scale (PR-CBS) is a recently validated instrument used to measure caregiver burden in this population. Methods We performed a cross-sectional study of caregiver burden for caregivers of children with kidney failure receiving dialysis at three pediatric centers. Caregivers completed the PR-CBS instrument as part of a larger qualitative study of caregiver experience. We performed descriptive statistics. T-tests were used to examine differences between dialysis modality and within key demographics. Multivariate linear regression was utilized to assess associations between significant factors and total score. Results Ten caregivers of children receiving peritoneal dialysis (PD) and 21 receiving hemodialysis (HD) participated. Total burden score and mean score for every domain was higher for caregivers of children on HD compared to PD. PR-CBS score was significantly associated with younger child age and married status in caregivers. In adjusted multivariate analysis, dialysis modality and married marital status were significantly associated with PR-CBS score. Conclusions This study found that dialysis caregivers experience significant caregiver burden and demonstrates the utility of the PR-CBS in an American population. We found higher burdens among HD caregivers, younger children, and married caregivers. While these findings must be replicated on a larger scale, they suggest possible areas for targeted interventions to improve the quality of life of children with kidney failure and their families. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 14 June 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (12) , 3945-3951
Caregiver burden in pediatric dialysis: application of the Paediatric Renal Caregiver Burden Scale
Background Caring for a child with kidney failure on dialysis profoundly impacts caregivers’ lives, yet the depth of this burden is not well understood. The Paediatric Renal Caregiver Burden Scale (PR-CBS) is a recently validated instrument used to measure caregiver burden in this population. Methods We performed a cross-sectional study of caregiver burden for caregivers of children with kidney failure receiving dialysis at three pediatric centers. Caregivers completed the PR-CBS instrument as part of a larger qualitative study of caregiver experience. We performed descriptive statistics. T-tests were used to examine differences between dialysis modality and within key demographics. Multivariate linear regression was utilized to assess associations between significant factors and total score. Results Ten caregivers of children receiving peritoneal dialysis (PD) and 21 receiving hemodialysis (HD) participated. Total burden score and mean score for every domain was higher for caregivers of children on HD compared to PD. PR-CBS score was significantly associated with younger child age and married status in caregivers. In adjusted multivariate analysis, dialysis modality and married marital status were significantly associated with PR-CBS score. Conclusions This study found that dialysis caregivers experience significant caregiver burden and demonstrates the utility of the PR-CBS in an American population. We found higher burdens among HD caregivers, younger children, and married caregivers. While these findings must be replicated on a larger scale, they suggest possible areas for targeted interventions to improve the quality of life of children with kidney failure and their families. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information